Plant Health Care Share Discussion Threads

[pretax2] 01/6/2022 15:28

There's your answer OAPK. Dr Richards buys back.
True to his word - I like that.

[oapknob1] 29/5/2022 17:33

https://www.bio.org/gooddaybio-archive/good-day-bio-bill-would-boost-plant-biostimulantsBipartisan bill would boost plant biostimulantsBIO applauds the legislation, which would provide a "clear pathway to the marketplace" for plant biostimulant products.What are plant biostimulants? They're substances or microorganisms that, when applied to seeds, plants, or the soil around the roots, enhance nutrient uptake and efficiency, tolerance to heat or drought, crop quality, and/or yield-like Joyn Bio's microbes. And make agriculture more sustainable, too. The Plant Biostimulant Act, introduced Friday by U.S. Reps. Jimmy Panetta (D-CA) and Jim Baird (R-IN), "would create a uniform process for approving commercial plant biostimulant use and require more federal research on the technology's benefits for soil health," per the press release."This legislation will help give full federal recognition of plant biostimulants, and provide a clear pathway to the marketplace for the technology, which is an invaluable new category of agricultural inputs that will improve soil health, water quality, and the overall growth of plants," said Sarah Gallo, BIO's VP for Agriculture and Environment.BIO's long supported this technology-including in the 2018 Farm Bill, when BIO joined a coalition letter explaining the need for regulatory clarity.BIO's take: "Cutting-edge, innovative technologies such as plant biostimulant products will be critical to sustainably increasing food production to mitigate food price inflation and enhance agriculture's resiliency to the stresses of climate change," said BIO's Sarah Gallo.The context: A drought is now covering the western half of the U.S., including grain production areas of the upper Plains and Southwest-and food prices are rising worldwide. Now more than ever, we need technology like biostimulants to mitigate the impact of climate change and geopolitical challenges on the food supply.

[oapknob1] 27/5/2022 23:37

Has Dr Richards had his shares bought back after the clerical error sale ?

[pretax2] 25/5/2022 18:23

Spreadex buying now.
In, out, in, out.
Not compalining, up 6%

[oapknob1] 23/5/2022 07:51

PHC's revenue from sales of Saori to Nutrien is expected to exceed US$750k in the first half of 2022, growing to more than US$5m by 2025.-- Nutrien expects to treat approximately 150,000 hectares of soybeans in 2022, expanding to more than one million hectares by 2025.-- The Total Addressable Market for Saori in Brazil in 2022 is estimated at 40 million hectares of soybean fields.-- Saori-treated fields were healthier and more robust, with lower incidence of disease compared to untreated fields.

[oapknob1] 16/5/2022 09:48

The next launch will be PHC279 in the USA; we anticipate regulatory approval in the second half of 2022 and are making detailed plans with our partner Wilbur-Ellis to launch before the end of the year. We have submitted PHC949 for registration in the USA and anticipate that this will be launched in 2023,

[kaos3] 16/5/2022 08:55

pretax - they are positive in the commercial business - only (nice spin and use of words - definition of the word commercial business is not an accounting term I think) - not as a whole - eg old harpin as the main driver. and I do not know how much impact did destocking have on the profitability...

growth rate is at cca 30 %

total loss is (at the end of it all) huge to my standards - regarding the size of the operation.

growers are adopting the product - but is is on "experimental" basis - one has to get used to the huge land numbers in agriculture. few 10o k ha is not a lot for the real impact on the business

each product costs from 3 -10 mio to gain full traction and is throwing off cash - but with each sequential product costing less and less

that is in general how I do see things - might be wrong

[oapknob1] 16/5/2022 08:27

Spreadex cleared out?

[pretax2] 16/5/2022 08:15

Kaos
Did you see the presentation?
Revenues are up, this year the company’s become profitable. Growers are clearly adopting the products. Furthermore after years of development, requiring investor input, the company can now move forwards without investment money growing organically for the first time. Yes, growth will start slowly, but this is the time to buy if you want to get in at a good share price in my opinion.
The rest require a little patience.
I have time, others don’t. We’re not all the same us investors.

[kaos3] 16/5/2022 07:26

growers (farmers) tend to be extremely conservative and even when things work well it takes years to fully adopt the product into the regular use

growers are bombarded with the next big thing - and they all promise to improve growth by x %. poor farmers who must make a choice each year several times at each production turn.

so by using all the next wonder products - where does he get lol - it is a jungle and for a product to become standard is a looong process at very low probability - even if it is performing as on the label

imho - it would be very good it "bio plant vaccine" would be an obligatory product if used for BIO certification of the end product .....

[pretax2] 16/5/2022 07:13

You are entitled to your opinion.good luck elsewhere.

[my retirement fund] 16/5/2022 06:58

I'm with Ceritto here, this is currently univestable. Clear as mud and obviously intentionally so!

[davemac3] 16/5/2022 06:57

Sounded very positive in Investor presentation

[pretax2] 16/5/2022 06:44

If the products are as good as the trials suggest, growers will start to adopt them (especially with fertiliser prices doubling). There ought to be a snowball effect.
Better to be in at the bottom of an exponential curve I suppose.

[kaos3] 16/5/2022 04:55

the issue with PHC is the loong cycles - R&D, approval, initial production, distribution and adoption - what - 10 years? of huge effort - and costs

and once one product is on its way - it has to finance the next one and so on....

a very long way to the free cash flow and divis

growth is large and not huge - if compared with some other (IT) high tech

This one for myself is 5mall allocation for the long term - so I keep looking at it. non stop good news - but no FCF. even after 2025 we must see it first - to believe

[oapknob1] 15/5/2022 22:20

Does this mean JW will be pumping PHC on Twitter now?

[pretax2] 15/5/2022 13:25

hxxps://www.voxmarkets.co.uk/articles/plant-health-care-s-commercial-busines-ebitda-and-cash-positive-for-a-second-straight-year-8b4d4bf/

-------------------------------
View from Vox

Plant Health Care’s mission is to tap into the global market for biological products, a market which is growing at 12% per annum and is projected to be a $19 billion market by 2026.

Since 2018, the company has evolved its strategy from a focus on licensing its technology to major suppliers of agrochemicals, towards working with distributors. It is convinced that the company’s distributor partners will drive the adoption of its technologies over the coming years, to the benefit of the farming industry as it seeks to adopt more sustainable practices.

The Company’s latest agreement will see it distribute the Harpin αβ bio-stimulant product, ProAct®, into Argentina andUruguay, respectively, to further drive its commercial sales.

Ager Agro SAS (“Ager”), which supplied products to 10 million total treated hectares of crops in Argentina in 2021, was recently appointed as the group’s distributor across both markets.

Over 16 million hectares of soybeans were planted in Argentina in 2021. Furthermore, farmers are under increasing pressure to move to more environmentally and biologically friendly products to improve the sustainability of production, the company acknowledges.

In 2022, Plant Health Care’s commercial business is both profitable and cash generative, The Company said it expects this to deliver profitable growth for the business “in the years ahead.”

[oapknob1] 12/5/2022 15:08

Forecast for 2025 up from £25mill to £30+mill. Interesting start

[pretax2] 12/5/2022 09:09

It’s an excellent statement from a company developing global reach for their products which are clearly gaining traction. I was perfectly happy with the forward statement, in the current economic and geopolitical landscape, nothing can be too clear. Keeping powder dry on current year sales, maybe more released in the webinar today.
In profit and growing organically, a takeover target if ever I saw one.
Frankly, you have to look hard to find something not to like.
GLA

[cerrito] 12/5/2022 08:17

I had a sense of foreboding when they started the announcement commenting on the undoubted blue sky opportunities rather than the specifics of 2021 performance.
Outlook statement very wooly and no comment on current year trading. No comment on huge increase in admin expenses. Was expecting more specific sales figures for Saori .
Good to see decrease in inventory, noted no increase in trade payables and good that they referred to sales as those from the distributor to end client.
I have no specific comment on management changes which reflected the reality of what I perceive to have been happening.

[kaos3] 12/5/2022 08:08

the most exciting words - taking market share in a growing market !!

... Sales of the Group's Harpin product increased by 55% in 2021, as market shares grew in core markets; the Commercial business is profitable and cash generative. ...

[oapknob1] 12/5/2022 07:16

All sounding very positive "Mid-term sales of Saori(TM) are now expected to exceed the entire current revenue of Plant Health Care today and we plan to follow that with at least one major product launch every year."